醫(yī)療機構開展基因導向個體化給藥的機遇和瓶頸-展示頁
2025-01-28 00:10本頁面
【正文】 e N n Frequencie (%)CYP2C9 181 CCAA 166 CCAC 14 TCAA 1 VKORC1 182 AATTAA 149 AACTAA 5 AGCTAA 1 AGCTGA 26 GGCCGG 1 APOE 179 TTCC 130 TTCT 19 TCTT 1 TCTC 3 TCCC 23 CCCC 1 The frequencies of dilotype in VKORC1, CYP2C9 and APOE Warfarin mean daliy dose P valueW/W W/M+M/MVKORC1 rs9923231 177。52:10389 CYP2C19 Deficiency and Stent ThrombosisPooled Baseline Characteristics by CYP2C19 Genotype StatusCardiovascular Death by CYP2C19 genotypeCardiovascular Death by CYP2C19 genotypeMyocardial Infarction by CYP2C19 genotypeIschemic Stroke by CYP2C19 genotypeTiming of Events for Cardiovascular Death, Myocardial Infarction, or IschemicStroke and Stent Thrombosis如何確定劑量或換用其他藥物 ——瓶 頸弱代 謝300 mg?600 mg?普拉格雷？ARCTICGENE(Assessment With a Double Randomization of a Monitoring adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation and Interruption Versus Continuation of Double Antiplatelet Therapy, One Year After Stenting) study u 常用、唯一的口服抗凝藥物u 適應證u 心臟瓣膜置換（ INR： ）u 深靜脈血栓 （ INR： 23）u 肺栓塞 （ INR： 23）u 房顫 （ INR： 23）u 抗凝過度 —Bleeding（ 2~10%）u 抗凝不足 —Thrombosis（ ~2‰）u 反復調試，延長住院天數(shù)華法林個體化給藥華法林個體化給藥Woodcock J,et al., N Engl J Med 2023:360(8)。醫(yī)療機構開展基因導向個體化給藥的機遇和瓶頸北京大學三醫(yī)院胡永芳副教授研究基礎 ( 循證證據(jù)）臨床應用的瓶頸政策方面管理規(guī)定收費標準Outline for Report In what ways can doctors use pharmacogeics to help them t
教學課件相關推薦
鄂ICP備17016276號-1